JKN2403
/ Joincare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 21, 2026
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd
New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1